` MEB (Medibio Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

MEB
vs
S
S&P/ASX 300

Over the past 12 months, MEB has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +4% growth.

Stocks Performance
MEB vs S&P/ASX 300

Loading
MEB
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MEB vs S&P/ASX 300

Loading
MEB
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
MEB vs S&P/ASX 300

Loading
MEB
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Medibio Ltd vs Peers

S&P/ASX 300
MEB
VEEV
PME
2413
DOCS
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Medibio Ltd
Glance View

Market Cap
122m AUD
Industry
Health Care

Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. The firm offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company offers a software called MEBsleep, a medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. The Company’s subsidiaries include Bioprospect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Medibio Limited USA, Invatec Health Pty Ltd and Annapanna Pty Ltd.

MEB Intrinsic Value
Not Available
Back to Top